Satellos Bioscience (TSE:MSCL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Satellos Bioscience successfully closed a $40 million public offering, issuing over 63 million equity securities, to fund its Phase 2 clinical program for SAT-3247. The offering was led by Bloom Burton Securities Inc. and participated by several agents. The funds will support clinical development and general corporate needs.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
